0

Close
 
2022
Gynecological Cancer Drugs Market

Gynecological Cancer Drugs Market

by Therapeutic Modality (Chemotherapy, Targeted Therapy, Hormonal Therapy), by Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer): Global Opportunity Analysis and Industry Forecast, 2020-2030
Update Available On-Demand

LS : Pharmaceuticals
✷  Report Code: A03071
Apr 2022 | Pages: 190
Tables: 118
Charts: 56

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

The global Gynecological Cancer Drugs Market Size was valued at $11.6 billion in 2020 and is projected to reach $21.8 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030.

Gynecological Cancer refers to a group of cancers that affect the reproductive organs of a female such as an endometrium, uterus, peritoneum, ovary, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus. Cancer is a specific disorder that can cause abnormal cell growth in any part of the body. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female.

The COVID-19 pandemic has a negative impact on the gynecological cancer drugs market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - ovarian, vulvar cancer, cervical cancer, endometrium cancer, vaginal cancer, fallopian tube cancer and among others. Thus, the COVID-19 pandemic has impacted the gynecological cancer drugs market. However, the situation is expected to gradually improve.

Gynecological Cancer Drugs Market, Gynecological Cancer Drugs Market Size, Gynecological Cancer Drugs Market Share, Gynecological Cancer Drugs Market Analysis, Gynecological Cancer Drugs Market Growth, Gynecological Cancer Drugs Market Opportunity, Gynecological Cancer Drugs Market Trends, Gynecological Cancer Drugs Market Forecast

The key factors that drive the Gynecological Cancer Drugs Market Growth are the rise in the incidence of gynecological cancers and an increase in investment from the government, public, &private sectors for cancer treatment are the key factors that drive the growth of the market. In addition, an increase in product approval is the key factor that is anticipated to drive the growth of the market in upcoming years. For instance, in November 2020, European Union (EU) approved Lynparza treatment with bevacizumab for homologous recombination deficient (HRD)-positive advanced ovarian cancer. In addition, the surge in cancer awareness and early screening of cancer also contribute to the growth of the Gynecological Cancer Drugs Industry. However, the high cost involved in new drug development coupled with the threat of failure & adverse effects associated with gynecological cancer drugs therapies poses to restrain the growth of the gynecological cancer drugs market. Conversely, the high potential of emerging economies and a higher number of potential drugs in the pipeline are the Gynecological Cancer Drugs Market Opportunity. 

The Gynecological Cancer Drugs Industry is segmented by therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Therapeutic Modality Segment Review

Gynecological Cancer Drugs Market
By Therapeutic Modality

Your browser does not support the canvas element.

The targeted therapy segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy generated the highest revenue in 2020. Owing to the adoption of target therapy across the world, targeted therapy offers many advantages as it interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes, which stop the growth of various types of cancers. Major factors that influenced the gynecology cancer drugs market growth include the fewer adverse effects of the therapy and the availability of a number of targeted therapeutics. 

Indication Segment Review

Gynecological Cancer Drugs Market
By Indication

Your browser does not support the canvas element.

The cervical cancer segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020, and this trend is expected to continue during the forecast period. As HPV is the major causative agent for cervical cancer, thus HPV vaccine is used in most of the developed regions of the world for the prevention against the disease.

Region Segment Review

Gynecological Cancer Drugs Market

Region-wise, North America dominated the Gynecological Cancer Drugs Market Share in 2020 and is expected to be dominant during the forecast period, owing to the presence of large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, arise in research and development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to an increase in the number of cancer-affected populations and a rise in awareness related to different cancers.

The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gynecological cancer drugs market analysis from 2020 to 2030 to identify the prevailing gynecological cancer drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gynecological cancer drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gynecological cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

 Gynecological Cancer Drugs Market Report Highlights

Aspects Details
By Indication
  • Cervical Cancer
  • Uterine Cancer
  • Ovarian Cancer
  • Vaginal & Vulvar Cancer
By Therapeutic Modality
  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest Of Asia Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players APOTEX INC, TEVA PHARMACEUTICAL INDUSTRIES LTD, GLAXOSMITHKLINE PLC, NOVARTIS AG, MERCK & CO., INC, BRISTOL-MYERS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD, ASTRAZENECA PLC, PFIZER INC, ELI LILLY AND COMPANY
 

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Chemotherapy

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Targeted Therapy

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Hormonal Therapy

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

  • CHAPTER 5: GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Cervical Cancer

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Uterine Cancer

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Ovarian Cancer

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

    • 5.5 Vaginal & Vulvar Cancer

      • 5.5.1 Key market trends, growth factors and opportunities

      • 5.5.2 Market size and forecast, by region

      • 5.5.3 Market analysis by country

  • CHAPTER 6: GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 North America

      • 6.2.1 Key trends and opportunities

      • 6.2.2 North America Market size and forecast, by By Therapeutic Modality

      • 6.2.3 North America Market size and forecast, by By Indication

      • 6.2.4 North America Market size and forecast, by country

        • 6.2.4.1 U.S.
          • 6.2.4.1.1 Market size and forecast, by By Therapeutic Modality
          • 6.2.4.1.2 Market size and forecast, by By Indication
        • 6.2.4.2 Canada
          • 6.2.4.2.1 Market size and forecast, by By Therapeutic Modality
          • 6.2.4.2.2 Market size and forecast, by By Indication
        • 6.2.4.3 Mexico
          • 6.2.4.3.1 Market size and forecast, by By Therapeutic Modality
          • 6.2.4.3.2 Market size and forecast, by By Indication

    • 6.3 Europe

      • 6.3.1 Key trends and opportunities

      • 6.3.2 Europe Market size and forecast, by By Therapeutic Modality

      • 6.3.3 Europe Market size and forecast, by By Indication

      • 6.3.4 Europe Market size and forecast, by country

        • 6.3.4.1 Germany
          • 6.3.4.1.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.1.2 Market size and forecast, by By Indication
        • 6.3.4.2 France
          • 6.3.4.2.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.2.2 Market size and forecast, by By Indication
        • 6.3.4.3 U.K.
          • 6.3.4.3.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.3.2 Market size and forecast, by By Indication
        • 6.3.4.4 Italy
          • 6.3.4.4.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.4.2 Market size and forecast, by By Indication
        • 6.3.4.5 Spain
          • 6.3.4.5.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.5.2 Market size and forecast, by By Indication
        • 6.3.4.6 Rest of Europe
          • 6.3.4.6.1 Market size and forecast, by By Therapeutic Modality
          • 6.3.4.6.2 Market size and forecast, by By Indication

    • 6.4 Asia-Pacific

      • 6.4.1 Key trends and opportunities

      • 6.4.2 Asia-Pacific Market size and forecast, by By Therapeutic Modality

      • 6.4.3 Asia-Pacific Market size and forecast, by By Indication

      • 6.4.4 Asia-Pacific Market size and forecast, by country

        • 6.4.4.1 Japan
          • 6.4.4.1.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.1.2 Market size and forecast, by By Indication
        • 6.4.4.2 China
          • 6.4.4.2.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.2.2 Market size and forecast, by By Indication
        • 6.4.4.3 Australia
          • 6.4.4.3.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.3.2 Market size and forecast, by By Indication
        • 6.4.4.4 India
          • 6.4.4.4.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.4.2 Market size and forecast, by By Indication
        • 6.4.4.5 South Korea
          • 6.4.4.5.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.5.2 Market size and forecast, by By Indication
        • 6.4.4.6 Rest Of Asia Pacific
          • 6.4.4.6.1 Market size and forecast, by By Therapeutic Modality
          • 6.4.4.6.2 Market size and forecast, by By Indication

    • 6.5 LAMEA

      • 6.5.1 Key trends and opportunities

      • 6.5.2 LAMEA Market size and forecast, by By Therapeutic Modality

      • 6.5.3 LAMEA Market size and forecast, by By Indication

      • 6.5.4 LAMEA Market size and forecast, by country

        • 6.5.4.1 Brazil
          • 6.5.4.1.1 Market size and forecast, by By Therapeutic Modality
          • 6.5.4.1.2 Market size and forecast, by By Indication
        • 6.5.4.2 Saudi Arabia
          • 6.5.4.2.1 Market size and forecast, by By Therapeutic Modality
          • 6.5.4.2.2 Market size and forecast, by By Indication
        • 6.5.4.3 South Africa
          • 6.5.4.3.1 Market size and forecast, by By Therapeutic Modality
          • 6.5.4.3.2 Market size and forecast, by By Indication
        • 6.5.4.4 Rest of LAMEA
          • 6.5.4.4.1 Market size and forecast, by By Therapeutic Modality
          • 6.5.4.4.2 Market size and forecast, by By Indication

  • CHAPTER 7: COMPANY LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top winning strategies

    • 7.3. Product Mapping of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Key developments

  • CHAPTER 8: COMPANY PROFILES

    • 8.1 APOTEX INC

      • 8.1.1 Company overview

      • 8.1.2 Company snapshot

      • 8.1.3 Operating business segments

      • 8.1.4 Product portfolio

      • 8.1.5 Business performance

      • 8.1.6 Key strategic moves and developments

    • 8.2 ASTRAZENECA PLC

      • 8.2.1 Company overview

      • 8.2.2 Company snapshot

      • 8.2.3 Operating business segments

      • 8.2.4 Product portfolio

      • 8.2.5 Business performance

      • 8.2.6 Key strategic moves and developments

    • 8.3 BRISTOL-MYERS SQUIBB COMPANY

      • 8.3.1 Company overview

      • 8.3.2 Company snapshot

      • 8.3.3 Operating business segments

      • 8.3.4 Product portfolio

      • 8.3.5 Business performance

      • 8.3.6 Key strategic moves and developments

    • 8.4 ELI LILLY AND COMPANY

      • 8.4.1 Company overview

      • 8.4.2 Company snapshot

      • 8.4.3 Operating business segments

      • 8.4.4 Product portfolio

      • 8.4.5 Business performance

      • 8.4.6 Key strategic moves and developments

    • 8.5 F. HOFFMANN-LA ROCHE LTD

      • 8.5.1 Company overview

      • 8.5.2 Company snapshot

      • 8.5.3 Operating business segments

      • 8.5.4 Product portfolio

      • 8.5.5 Business performance

      • 8.5.6 Key strategic moves and developments

    • 8.6 GLAXOSMITHKLINE PLC

      • 8.6.1 Company overview

      • 8.6.2 Company snapshot

      • 8.6.3 Operating business segments

      • 8.6.4 Product portfolio

      • 8.6.5 Business performance

      • 8.6.6 Key strategic moves and developments

    • 8.7 MERCK & CO., INC

      • 8.7.1 Company overview

      • 8.7.2 Company snapshot

      • 8.7.3 Operating business segments

      • 8.7.4 Product portfolio

      • 8.7.5 Business performance

      • 8.7.6 Key strategic moves and developments

    • 8.8 NOVARTIS AG

      • 8.8.1 Company overview

      • 8.8.2 Company snapshot

      • 8.8.3 Operating business segments

      • 8.8.4 Product portfolio

      • 8.8.5 Business performance

      • 8.8.6 Key strategic moves and developments

    • 8.9 PFIZER INC

      • 8.9.1 Company overview

      • 8.9.2 Company snapshot

      • 8.9.3 Operating business segments

      • 8.9.4 Product portfolio

      • 8.9.5 Business performance

      • 8.9.6 Key strategic moves and developments

    • 8.10 TEVA PHARMACEUTICAL INDUSTRIES LTD

      • 8.10.1 Company overview

      • 8.10.2 Company snapshot

      • 8.10.3 Operating business segments

      • 8.10.4 Product portfolio

      • 8.10.5 Business performance

      • 8.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)
    TABLE 2. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR CHEMOTHERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 3. GYNECOLOGICAL CANCER DRUGS MARKET CHEMOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR TARGETED THERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 5. GYNECOLOGICAL CANCER DRUGS MARKET TARGETED THERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR HORMONAL THERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 7. GYNECOLOGICAL CANCER DRUGS MARKET HORMONAL THERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)
    TABLE 9. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR CERVICAL CANCER, BY REGION , 2020-2030,($MILLION)
    TABLE 10. GYNECOLOGICAL CANCER DRUGS MARKET CERVICAL CANCER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 11. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR UTERINE CANCER, BY REGION , 2020-2030,($MILLION)
    TABLE 12. GYNECOLOGICAL CANCER DRUGS MARKET UTERINE CANCER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 13. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR OVARIAN CANCER, BY REGION , 2020-2030,($MILLION)
    TABLE 14. GYNECOLOGICAL CANCER DRUGS MARKET OVARIAN CANCER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 15. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE, FOR VAGINAL & VULVAR CANCER, BY REGION , 2020-2030,($MILLION)
    TABLE 16. GYNECOLOGICAL CANCER DRUGS MARKET VAGINAL & VULVAR CANCER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 17. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 18. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)
    TABLE 19. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)
    TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 27. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)
    TABLE 28. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)
    TABLE 29. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 30. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 32. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 34. U.K. GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 35. U.K. GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 36. ITALY GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 38. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 40. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 42. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)
    TABLE 43. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)
    TABLE 44. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 45. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 47. CHINA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 49. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 50. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 52. INDIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 53. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 55. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 56. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 57. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY THERAPEUTIC MODALITY, 2020-2030,($MILLION)
    TABLE 58. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY BY INDICATION, 2020-2030,($MILLION)
    TABLE 59. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 60. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 62. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 63. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 65. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 66. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET BY BY THERAPEUTIC MODALITY 2020-2030,($MILLION)
    TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET BY BY INDICATION 2020-2030,($MILLION)
    TABLE 68.APOTEX INC: COMPANY SNAPSHOT
    TABLE 69.APOTEX INC: OPERATING SEGMENTS
    TABLE 70.APOTEX INC: PRODUCT PORTFOLIO
    TABLE 71.APOTEX INC: NET SALES,
    TABLE 72.APOTEX INC: KEY STRATERGIES
    TABLE 73.ASTRAZENECA PLC: COMPANY SNAPSHOT
    TABLE 74.ASTRAZENECA PLC: OPERATING SEGMENTS
    TABLE 75.ASTRAZENECA PLC: PRODUCT PORTFOLIO
    TABLE 76.ASTRAZENECA PLC: NET SALES,
    TABLE 77.ASTRAZENECA PLC: KEY STRATERGIES
    TABLE 78.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
    TABLE 79.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
    TABLE 80.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
    TABLE 81.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
    TABLE 82.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
    TABLE 83.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 84.ELI LILLY AND COMPANY: OPERATING SEGMENTS
    TABLE 85.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 86.ELI LILLY AND COMPANY: NET SALES,
    TABLE 87.ELI LILLY AND COMPANY: KEY STRATERGIES
    TABLE 88.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
    TABLE 89.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
    TABLE 90.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
    TABLE 91.F. HOFFMANN-LA ROCHE LTD: NET SALES,
    TABLE 92.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
    TABLE 93.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
    TABLE 94.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
    TABLE 95.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
    TABLE 96.GLAXOSMITHKLINE PLC: NET SALES,
    TABLE 97.GLAXOSMITHKLINE PLC: KEY STRATERGIES
    TABLE 98.MERCK & CO., INC: COMPANY SNAPSHOT
    TABLE 99.MERCK & CO., INC: OPERATING SEGMENTS
    TABLE 100.MERCK & CO., INC: PRODUCT PORTFOLIO
    TABLE 101.MERCK & CO., INC: NET SALES,
    TABLE 102.MERCK & CO., INC: KEY STRATERGIES
    TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
    TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 106.NOVARTIS AG: NET SALES,
    TABLE 107.NOVARTIS AG: KEY STRATERGIES
    TABLE 108.PFIZER INC: COMPANY SNAPSHOT
    TABLE 109.PFIZER INC: OPERATING SEGMENTS
    TABLE 110.PFIZER INC: PRODUCT PORTFOLIO
    TABLE 111.PFIZER INC: NET SALES,
    TABLE 112.PFIZER INC: KEY STRATERGIES
    TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
    TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
    TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
    TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,
    TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
    FIGURE 2.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
    FIGURE 3.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.GYNECOLOGICAL CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.GYNECOLOGICAL CANCER DRUGS MARKET,BY BY THERAPEUTIC MODALITY,2020(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HORMONAL THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 16.GYNECOLOGICAL CANCER DRUGS MARKET,BY BY INDICATION,2020(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF UTERINE CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OVARIAN CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VAGINAL & VULVAR CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
    FIGURE 21.GYNECOLOGICAL CANCER DRUGS MARKET BY REGION,2020
    FIGURE 22.U.S. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 23.CANADA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 24.MEXICO GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 25.GERMANY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 26.FRANCE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 27.U.K. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 28.ITALY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 29.SPAIN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 30.REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 31.JAPAN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 32.CHINA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 33.AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 34.INDIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 35.SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 36.REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 37.BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 38.SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 39.SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 40.REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
    FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 45.COMPETITIVE DASHBOARD
    FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 47.APOTEX INC.: NET SALES ,($MILLION)
    FIGURE 48.ASTRAZENECA PLC.: NET SALES ,($MILLION)
    FIGURE 49.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
    FIGURE 50.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
    FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
    FIGURE 52.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
    FIGURE 53.MERCK & CO., INC.: NET SALES ,($MILLION)
    FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 55.PFIZER INC.: NET SALES ,($MILLION)
    FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES ,($MILLION)

 
 

According to the CXOs, the adoption of gynecological cancer drugs is expected to increase in the near future, owing to a high prevalence rate of gynecological cancers globally. The gynecological cancer drugs market has piqued the interest of healthcare providers owing to continuous R&D in the field of oncology drugs.This has led to the emergence of new treatment options for patients suffering from cancer. In addition, increase ininvestment from various organizations for cancer treatment and surge in risk factors that further drive the market growth.

According to the perspective of CXOs, North America is expected to dominate the global gynecological cancer drugsmarket during the forecast period, followed by Europe. In addition, Asia-Pacific and LAMEA are expected to offerlucrative opportunities to market players throughout the forecast period.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of the Gynecological Cancer Drugs market is $11,622.5 million in 2020

A. $21,791.44 million is the estimated industry size for Gynecological Cancer Drugs in 2030

A. The upcoming trends of the Gynecological Cancer Drugs Market are high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sector for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth

A. North America is the largest regional market for Gynecological Cancer Drugs

A. Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG are the top companies to hold the market share in Gynecological Cancer Drugs

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Gynecological Cancer Drugs Market

Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,565
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Data Pack
  • $3,961
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Single User
  • $5,540
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Five Users
  • $6,654
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)

  • Enterprise
    License/PDF

  • $10,280
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers